retatrutide type 2 diabetes phase 2 trial 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide Results: 28.3% Weight Loss
Pay in 4 interest-free payments of $6.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5











![Klow vs Glow Peptide: 5 Key Differences [Comparison 2026]](https://klow-peptide.com/images/content/heroes/klow-vs-glow.jpg)










